Known targets — ChEMBL curated mechanism
KCNA5KCND3KCNH2KCNJ3KCNJ5SCN5A
The experimentally established mechanism targets of Vernakalant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 known ✓ | P22460 | 6/20 | 0.98 |
| ▸ | SCN5A known ✓ | Q14524 | 6/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCND2 | Q9NZV8 | 5/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vernakalant SCHEMBL2632638 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL2624885 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL411090 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL12203901 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL411046 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL14390243 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL2624888 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL14390429 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL13097995 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 | |
| Vernakalant SCHEMBL2624887 | 1.00 | SLC6A4 (1.00) | SLC6A4KCNA5SCN5AKCND2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018031216-A1 | TREATMENT OF DISORDERS OF SEXUAL AROUSAL WITH LOCAL APPLICATION OF AGENTS THAT INCREASE MEMBRANE EXCITABILITY | ROTHMAN STEVEN (US) | 2018-02-15 | — | — | WO | claimed |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP (CA) | 2016-01-14 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2013-07-04 | — | — | US | disclosed |
| EP-2606139-A2 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE | Codexis, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024104-A2 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE | CODEXIS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8058304-B2 | Merged ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2011-11-15 | — | — | US | disclosed |
| US-20090088464-A1 | Merged ion channel modulating compounds and Uses Thereof | CARDIOME PHARMA CORP. (CA) | 2009-04-02 | — | — | US | disclosed |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | CARDIOME PHARMA CORP. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-20080004333-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004333-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7259184-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-7259184-B2 | Ion channel modulating compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-08-21 | — | — | US | disclosed |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-08-16 | — | — | US | disclosed |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | CARDIOME PHARMA CORP. (CA) | 2007-08-16 | — | — | US | disclosed |
| US-20070088075-A1 | Deuterated aminocyclohexyl ether compounds and processes for preparing same | CARDIOME PHARMA CORP. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070088075-A1 | Deuterated aminocyclohexyl ether compounds and processes for preparing same | CARDIOME PHARMA CORP. (CA) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171077-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885KCNH2 8/4885 |
| US-20070088075-A1 | Deuterated aminocyclohexyl ether compounds and processes for preparing same | DDC, HDHD5, DDT | KCNA5 2363/4885SCN5A 4208/4885KCNH2 890/4885 |
| US-20080004333-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885KCNH2 8/4885 |
| US-20160008322-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885KCNH2 8/4885 |
| US-20070190156-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885KCNH2 8/4885 |
| US-20140314685-A1 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, KCNN2 | KCNA5 26/4885SCN5A 54/4885KCNH2 8/4885 |
| US-20090088464-A1 | Merged ion channel modulating compounds and Uses Thereof | KCNJ2, CACNA1B, TRPM5 | KCNA5 30/4885SCN5A 94/4885KCNH2 56/4885 |
| US-20080188547-A1 | USES OF ION CHANNEL MODULATING COMPOUNDS | KCNN1, KCNN2, KCNN3 | KCNA5 48/4885SCN5A 49/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.